Literature DB >> 12079301

Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

Ugur Saygili1, Serkan Guclu, Turhan Uslu, Oktay Erten, Namik Demir, Ata Onvural.   

Abstract

OBJECTIVE: The aim of this study was to investigate the predictive value of serum CA-125 levels to ability of optimal primary cytoreduction in patients with advanced epithelial ovarian carcinoma.
METHODS: Preoperative serum CA-125 levels were determined by a commercial enzyme immunoassay kit in a series of 92 patients with stage IIIC epithelial ovarian carcinoma. The abilities of various cutoff value of CA-125 to predict suboptimal cytoreductive surgery were determined. A receiver operating characteristic curve was used to find the most clinically useful CA-125 cutoff value.
RESULTS: Optimal cytoreduction was obtained in 48 patients (52%) using the diameter of the largest residual tumor nodule less than 1 cm. Receiver operating characteristic curve showed that the most clinically suitable CA-125 cutoff value was 500 U/ml. Forty-seven patients (51%) had preoperative serum CA-125 levels below 500 U/ml. Of these patients, optimal cytoreductive surgery was performed in 36 (77%). Of the 45 patients with serum CA-125 levels greater than 500 U/ml, optimal cytoreductive surgery was achieved in 12 (27%). True- and false-positive rates were 73 and 23%, respectively.
CONCLUSIONS: Although our results showed that preoperative serum CA-125 levels might predict the optimal resectable patients, larger prospective studies are needed to prove its predictivity. Gynecologic oncologists should evaluate the sum of all criteria until more data are available. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079301     DOI: 10.1006/gyno.2002.6719

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 2.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

3.  A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Authors:  Mona Aarenstrup Karlsen; Carsten Fagö-Olsen; Estrid Høgdall; Tine Henrichsen Schnack; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Magnus Christian Lydolph; Svend Aage Engelholm; Claus Høgdall
Journal:  Tumour Biol       Date:  2016-07-20

Review 4.  The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma.

Authors:  Joseph Menczer; Erez Ben-Shem; Abraham Golan; Tally Levy
Journal:  Rambam Maimonides Med J       Date:  2015-01-29

5.  Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer

Authors:  Maliheh Arab; Farzaneh Jamdar; Maryam Sadat Hosseini; Robabe Ghodssi- Ghasemabadi; Farah Farzaneh; Tahereh Ashrafganjoei
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

6.  Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study.

Authors:  Mengdi Fu; Chengjuan Jin; Shuai Feng; Zongyang Jia; Lekai Nie; Yang Zhang; Jin Peng; Xia Wang; Hualei Bu; Beihua Kong
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

7.  Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.

Authors:  G Ferrandina; G Sallustio; A Fagotti; G Vizzielli; A Paglia; E Cucci; A Margariti; L Aquilani; G Garganese; G Scambia
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

8.  Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.

Authors:  Aurélie Pelissier; Aurélie Roulot; Béatrice Guéry; Claire Bonneau; Dominique Bellet; Roman Rouzier
Journal:  J Ovarian Res       Date:  2016-09-27       Impact factor: 4.234

9.  The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers.

Authors:  G N A Winarno; Y M Hidayat; S Soetopo; S R Krisnadi; M D L Tobing; S Rauf
Journal:  BMC Res Notes       Date:  2020-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.